Lab
Regional Cancer Care Associates LLC
Regional Cancer Care Associates LLC was paid $5.36M by Medicaid between Jan 2018 and Nov 2024, across 42 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoREGIONAL CANCER CARE ASSOCIATES LLC
TOMS RIVER, NJ 08753
TOMS RIVER, NJ 08753
33aNPI1801850243assigned 04/13/2006
33bProvider typeClinical Medical Laboratory
28Total paid$5.36M
24GClaims295,369
24DCodes billed42
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New Jersey
Rank by total paid#38 of 122
Median peer was paid$1.29M
This provider vs. median4.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,634 | $751K | |
| 2019 | 24,476 | $798K | |
| 2020 | 31,954 | $725K | |
| 2021 | 34,303 | $598K | |
| 2022 | 52,785 | $786K | |
| 2023 | 51,655 | $821K | |
| 2024incomplete | 66,562 | $877K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 68,728 | 47,937 | $1.98M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 27% | 45,417 | 27,756 | $1.45M |
| J2505 | Injection, pegfilgrastim, 6 mg | 8.3% | 129 | 90 | $444K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 7.9% | 696 | 216 | $424K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.9% | 102,823 | 66,397 | $318K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.0% | 8,878 | 6,468 | $212K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 3.2% | 7,695 | 2,289 | $169K |
| 77427 | 1.9% | 1,648 | 558 | $100K | |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 1.0% | 3,730 | 1,270 | $54K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 681 | 527 | $36K |
| 77014 | <1% | 2,295 | 159 | $32K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 629 | 353 | $25K |
30 more codes
| 77334 | <1% | 246 | $24K | |
| 96367 | <1% | 1,037 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,117 | $12K |
| 99223 | Prolong inpt eval add15 m | <1% | 382 | $9K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 12,621 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 277 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,837 | $7K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 180 | $4K |
| 99205 | Prolong outpt/office vis | <1% | 71 | $4K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 56 | $3K |
| 88185 | <1% | 28 | $3K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 31 | $3K |
| 85027 | <1% | 1,193 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 173 | $2K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 71 | $2K |
| 77300 | <1% | 14 | $956.66 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $876.73 |
| 77263 | <1% | 18 | $453.38 | |
| 85097 | <1% | 20 | $393.68 | |
| 88184 | <1% | 28 | $347.79 | |
| 99459 | <1% | 46 | $308.93 | |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement | <1% | 917 | $184.00 |
| 88189 | <1% | 12 | $146.88 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 136 | $121.78 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 268 | $107.19 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 19 | $87.55 |
| S0028 | Injection, famotidine, 20 mg | <1% | 40 | $71.16 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 90 | $64.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44 | $34.56 |
| J3490 | Unclassified drugs | <1% | 36 | $3.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJORDAN, TERRILL (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Rcca MD LLC | Olney, MD | $1.31M |
| Regional Cancer Care Associates LLC | Belleville, NJ | $1.06M |
| Regional Cancer Care Associates LLC | Manchester, CT | $686K |
| Regional Cancer Care Associates, L.L.C. | Washington, DC | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.